Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation

Chronic localized granulomatous dermatoses present a therapeutic challenge, particularly in cosmetically sensitive areas where standard treatments often prove insufficient or intolerable. We describe a technique using intralesional injection of adalimumab to treat chronic refractory cutaneous granulomatous inflammation. This method highlights the potential of intralesional tumor necrosis factor (TNF) α inhibition as a targeted treatment option in refractory cutaneous granulomatous inflammation, offering localized efficacy while minimizing systemic exposure.